EISAI CO

The Dame Barbara Windsor Dementia Goals programme, launched in 2022 with £95 million and later increased to £120 million, aims to accelerate dementia treatment development. Co-Chaired by Hilary Evans-Newton and Nadeem Sarwar, it includes initiatives like the Neurodegeneration Initiative and a Clinical Trials Delivery Accelerator. Key appointments include Scott Mitchell as People’s Champion and Ruth McKernan as Chair of the Scientific Advisory Board. Funding supports innovations in biomarkers and clinical trials, with additional £20 million announced in 2023 for the CTDA.

Bioarctic's partner Eisai announces Mexican Medicines Agency approval of Leqembi (lecanemab) for early Alzheimer's treatment, following US, Japan, China, South Korea, Hong Kong, Israel, UAE, and UK approvals. The European Medicines Agency's CHMP also issued a positive recommendation.

Eisai and Biogen announce COFEPRIS approval of LEQEMBI® (lecanemab) for early Alzheimer’s disease, targeting soluble and insoluble Aβ aggregates. LEQEMBI is the first treatment shown to reduce disease progression and cognitive decline, already approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the UAE, and Great Britain. The approval is based on the Phase 3 Clarity AD study, which met primary and secondary endpoints with significant results.

Eisai announced COFEPRIS approval of Leqembi (lecanemab) for early Alzheimer's disease in Mexico. Leqembi, developed by BioArctic and Eisai, targets amyloid-beta aggregates, reducing disease progression. It's also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain.

BioArctic's partner Eisai announces COFEPRIS approval of Leqembi for early Alzheimer's disease in Mexico. Leqembi reduces Aβ protofibrils and plaques, slowing cognitive decline. It's also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain. Based on Phase 3 Clarity AD trial data, Leqembi met primary and secondary endpoints. Collaboration with BioArctic began in 2005, with Eisai leading clinical development and commercialization.

Eisai discontinued lorcaserin trials in Dravet syndrome due to recruitment issues, prompting patients to stop the drug by October. The DSF engaged with Eisai to explore alternatives, recognizing the reliance on lorcaserin after other treatments failed. The trials' challenges coincided with FDA approval of fenfluramine, affecting enrollment.